Work

An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies

Year: 2019

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.07.209

Authors: Matthew Davids, Peter Hillmen, Marco Montillo, Julio Delgado, Bryone Kuss, Constantine Tam, Ulrich Jäger, Paolo Ghia, Stephan Stilgenbauer, Florence Cymbalista, Stephanie Lustgarten, David Weaver, Hagop Youssoufian, Ian Flinn

Institutions: Dana-Farber Cancer Institute, St James's University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Flinders University, Flinders Medical Centre, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, Medical University of Vienna, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Universitätsklinikum des Saarlandes, University Hospital Ulm, Hôpital Avicenne, Verastem (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2970760025

FWCI:

Cites:

Cited by:

Related to: 10